XBIT - XBiotech

-

$undefined

N/A

(N/A)

XBiotech NasdaqGS:XBIT XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Location: 5217 Winnebago Lane, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, United States | Website: https://www.xbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-63.21M

Cash

155.9M

Avg Qtr Burn

-7.62M

Short % of Float

4.53%

Insider Ownership

35.07%

Institutional Own.

14.83%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Hutrukin Details
Brain disease, Ischemic stroke

Phase 2

Update

Natrunix + Methotrexate (MTX) Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

Natrunix w/ ON+5FU+LV Details
Cancer, Pancreatic cancer

Phase 1/2

Update

Phase 1

Update

514G3 Details
Bacterial infection, Methicillin-resistant staphylococcus aureus

Failed

Discontinued

Bermekimab Details
Skin disease/disorder

Failed

Discontinued

Bermekimab Details
Skin disease/disorder, Hidradenitis suppurativa

Failed

Discontinued